LinaTech
With over 30 years of expertise in radiotherapy, LinaTech delivers end-to-end solutions from core accelerator components to fully integrated systems. Since receiving FDA clearance in 2024, VenusX has been installed in 8 countries across four continents and received regulatory approvals in 12 countries and regions—positioning LinaTech as a global trusted partner against cancer.
The Venus series linear accelerator features the world's first orthogonal dual‑layer multi-leaf collimator (OMLC), which precisely sculpts radiation beams to minimize leakage dose and maximize target conformity. One system covers full spectrum of precision radiotherapy—including Volumetric Modulated Arc Therapy (VMAT), Image-Guided Radiotherapy (IGRT), Stereotactic Radiotherapy (SRT), Adaptive Radiotherapy (ART), etc. LinaTech is committed to empowering healthcare institutions with reliable technologies, professional services, and long-term partnerships, thereby strengthening radiotherapy capabilities to extend the benefits of precision treatments to patients worldwide.
Milestones
Global Footprint
Technology Export & Localized Collaboration
Our products have obtained registration certificates in multiple countries. We acquired U.S. FDA
approval in 2024, and our services cover dozens of countries and regions worldwide.
China
Russia
Belarus
Kazakhstan
Austria
Korea
Hong Kong
Singapore
Malaysia
Indonesia
India
Bangladesh
Vietnam
Iran
Turkey
Tunisia
Zimbabwe
Nigeria
United States
Mexico
Colombia
Brazil
Peru
Chile
Corporate Culture
Mission
Vision
Values
Tenacity • Integrity
Hotline:+86 10 67888916
Time:8:00 - 18:00